Exploring the progression of angle-closure glaucoma over five years
The Beijing Angle Closure Progression Study (BAPS)
This study looks at how often people with early signs of angle-closure glaucoma develop more serious forms of the disease over five years to help find ways to prevent vision loss.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 825 (estimated) |
| Ages | 40 Years to 75 Years |
| Sex | All |
| Sponsor | Peking University People's Hospital Academic / other |
| Locations | 1 site (Beijing, Beeijing) |
| Trial ID | NCT05563623 on ClinicalTrials.gov |
What this trial studies
The Beijing Angle Closure Progression Study aims to investigate the five-year incidence of primary angle closure suspect (PACS) progressing to primary angle closure (PAC) or primary angle closure glaucoma (PACG). This observational study will assess potential risk factors associated with disease progression, providing valuable insights for managing PACS. By understanding the natural history of angle-closure diseases, the study seeks to inform strategies that could prevent severe visual impairment caused by PACG, which is a leading cause of irreversible blindness worldwide.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with primary angle closure suspect (PACS) who meet specific gonioscopic criteria and can provide informed consent.
Not a fit: Patients who have already progressed to primary angle closure or primary angle closure glaucoma, or those with significant prior ocular surgeries, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients at risk of developing severe visual impairment from angle-closure glaucoma.
How similar studies have performed: While previous studies have reported on the prevalence of PAC and PACG, this study's focus on the longitudinal progression of PACS in an Asian population is relatively novel and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * "Static" gonioscopy identifying 6 or more clock hours of angle circumference in which the posterior (usually pigmented) trabecular meshwork cannot be seen in both eyes with no peripheral anterior synechiae, and normal intraocular pressure (IOP), optic nerve and visual field. * Able to provide informed consent Exclusion Criteria: * Any evidence of primary angle closure (a narrow angle as defined above, but with PAS and/or IOP \> 21 mmHg) or primary angle closure glaucoma (visual field defect or glaucomatous optic neuropathy). * Previous intraocular surgery or laser treatment, such as cataract surgery, laser trabeculoplasty, trabeculectomy, laser peripheral iridectomy, and laser iridoplasty * Sign of prior acute attack, such as glaucomatous fleck, keratic precipitates, or iris atrophy. * Anterior segment structural abnormalities shown by examination, such as iris or ciliary body tumor. * Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, or lung disease, or terminal cancer. * Severe eye diseases, such as cataract, macular disease, and retinal detachment.
Where this trial is running
Beijing, Beeijing
- Peking University People's Hospital — Beijing, Beeijing, China (Recruiting)
Study contacts
- Study coordinator: Huijuan Wu, M.D. Ph.D.
- Email: dr_wuhuijuan@126.com
- Phone: 8613811293109
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.